Home β€Ί Stock analysis β€Ί NBIX

Neurocrine Biosciences (NBIX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

NBIX dips 0.9% to $135.71. Closed at $135.71, -0.91% vs the prior close of $136.95. Day range $135.55–$138.20, opened at $137.86.

Last close$135.71-0.91%
Day range135.55–138.20
Open137.86
Volume1.08M
52-week range122.14–186.12
Avg volume (20d)1.42M

NBIX daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” NBIX dips 0.9% to $135.71
Oct 15, 2026 β€” NBIX rises 0.8% to $136.95
Oct 14, 2026 β€” NBIX rises 0.6% to $135.91
Oct 13, 2026 β€” NBIX slides 4.4% to $135.13, a 3-month low
Oct 12, 2026 β€” NBIX dips 0.8% to $141.37
Oct 9, 2026 β€” NBIX rises 0.8% to $142.44
Oct 8, 2026 β€” NBIX dips 1.5% to $141.25
Oct 7, 2026 β€” NBIX dips 1.4% to $143.47
Oct 6, 2026 β€” NBIX rises 0.9% to $145.51, 3 up days in a row
Oct 5, 2026 β€” NBIX rises 0.7% to $144.21
Oct 2, 2026 β€” NBIX rises 1.8% to $143.18

NBIX latest news & SEC filings

Every SEC filing by or about NBIX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 15, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0000019617-26-000371

Oct 7, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001727606-26-000004

Sep 28, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0000914475-26-000045

Sep 15, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001894425-26-000020

Sep 15, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001504783-26-000019

Sep 15, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001818524-26-000006

Sep 15, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001201096-26-000018

Sep 15, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001567160-26-000009

Jul 31, 2026 Β· Form S-8 β€” Employee share plan registration

Registration of shares for employee stock plans (S-8)

Source: SEC EDGAR filing 0000914475-26-000040

Jul 31, 2026 Β· Form 8-K/A β€” Current report (amended)

Amended current report

Source: SEC EDGAR filing 0001193125-26-328470

Jul 31, 2026 Β· Form 10-Q β€” Quarterly report

Quarterly report (unaudited financial statements for the quarter)

Quarter ended Jun 30, 2026:

Source: SEC EDGAR filing 0000914475-26-000037

Jul 30, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

This is a results-day filing: the earnings press release is attached as an exhibit.

Source: SEC EDGAR filing 0000914475-26-000035

Jul 27, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0000019617-26-000313

Things to know before you trade NBIX

NBIX market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 2026137.86138.20135.55135.711.08M
Oct 15, 2026137.26138.23135.55136.951.38M
Oct 14, 2026133.94136.57132.25135.911.51M
Oct 13, 2026139.60139.93134.89135.131.57M
Oct 12, 2026142.37143.63140.89141.371.09M
Oct 9, 2026141.33143.55140.02142.441.02M
Oct 8, 2026142.88143.02140.34141.251.24M
Oct 7, 2026145.33145.88143.21143.471.14M
Oct 6, 2026145.56145.77141.39145.511.45M
Oct 5, 2026142.94146.92142.48144.211.75M
Oct 2, 2026141.41144.56140.36143.181.65M
Oct 1, 2026140.94143.74139.61140.712.05M
Sep 30, 2026138.33142.91137.63141.841.85M
Sep 29, 2026138.26141.07136.31138.351.50M
Sep 28, 2026137.76140.59136.78140.441.42M
Sep 25, 2026138.94138.94137.02138.401.17M
Sep 24, 2026138.54140.63137.00138.941.17M
Sep 23, 2026141.97142.25139.32139.491.75M
Sep 22, 2026144.17144.26141.78142.251.21M
Sep 21, 2026146.15146.26143.45143.961.39M

About Neurocrine Biosciences

Neurocrine Biosciences (NBIX) is listed on the Nasdaq and classified by the SEC under β€œBiological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 914475.

NBIX board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Kevin Charles GormanDirectorSep 15, 2026
Kyle GanoChief Executive OfficerSep 15, 2026
Gary A LyonsDirectorMay 29, 2026
George J MorrowDirectorMay 29, 2026
Johanna MercierDirectorMay 29, 2026
Leslie V NorwalkDirectorJul 30, 2026
Christine A PoonDirectorMay 29, 2026
Richard F PopsDirectorMay 29, 2026
William H RastetterDirectorMay 29, 2026
Stephen A SherwinDirectorSep 3, 2026
Shalini SharpDirectorMay 29, 2026

Executive officers

NameTitleLatest filing
Matt AbernethyChief Financial OfficerSep 15, 2026
Eric BenevichChief Commercial OfficerSep 15, 2026
David W. BoyerChief Corp. Affairs OfficerSep 15, 2026
Julie CookeChief Human Resources OfficerSep 15, 2026
Ingrid DelaetChief Regulatory OfficerSep 15, 2026
Kyle GanoChief Executive OfficerSep 15, 2026
Sanjay Chandru KeswaniChief Medical OfficerSep 15, 2026
Darin LippoldtChief Legal OfficerSep 15, 2026
Jude OnyiaChief Scientific OfficerSep 15, 2026
Andrew RatzChief Technical Operations OffMar 17, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
Sep 14, 2026Matt AbernethySale2,311$157.20
Sep 14, 2026Matt AbernethySale2,311$157.20
Sep 14, 2026Matt AbernethySale2,311$157.20
Sep 14, 2026Matt AbernethySale2,311$157.20
Sep 14, 2026David W. BoyerSale826$157.45
Sep 14, 2026David W. BoyerSale826$157.45
Sep 14, 2026David W. BoyerSale826$157.45
Sep 14, 2026David W. BoyerSale826$157.45
Sep 9, 2026Eric BenevichSale2,154$154.61
Sep 9, 2026Eric BenevichSale2,154$154.61
Sep 9, 2026Eric BenevichSale2,154$154.61
Sep 9, 2026Eric BenevichSale2,154$154.61
Jul 28, 2026Leslie V NorwalkSale1,250$182.01
Jul 28, 2026Leslie V NorwalkSale1,250$182.01
Jul 28, 2026Leslie V NorwalkSale1,250$182.01

NBIX financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025$2.86B$478.60M4.67$782.70M
Dec 31, 2024$2.36B$341.30M3.29$595.40M
Dec 31, 2023$1.89B$249.70M2.47$389.90M
Dec 31, 2022$1.49B$154.50M1.56$339.40M
Dec 31, 2021$1.13B$89.60M0.92$256.50M

Latest balance sheet: total assets $5.36B, total liabilities $1.67B, cash $332.40M (as of Jun 30, 2026).

NBIX earnings / results-day log

DateFilingClose that day
Jul 30, 20268-K Item 2.02 (results)$185.50
May 5, 20268-K Item 2.02 (results)$135.06
Feb 11, 20268-K Item 2.02 (results)$137.44
Oct 28, 20258-K Item 2.02 (results)$147.38
Jul 30, 20258-K Item 2.02 (results)$136.76
May 5, 20258-K Item 2.02 (results)$109.75
Feb 6, 20258-K Item 2.02 (results)$150.51
Oct 30, 20248-K Item 2.02 (results)$124.33
Aug 1, 20248-K Item 2.02 (results)β€”
May 1, 20248-K Item 2.02 (results)β€”
Feb 7, 20248-K Item 2.02 (results)β€”
Oct 31, 20238-K Item 2.02 (results)β€”

Related stocks Β· Biological Products, (No Diagnostic Substances)

Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on NBIX

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.